Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Vaxcyte Inc. (PCVX)

NASDAQ: PCVX · Biological Products, (No Diagnostic Substances) · San Carlos, CA

Our rating: Positive

Positive reaffirmed at $61.92, moderate conviction, November 5, 2026.

Breaks if: The Positive call is wrong if the lead program receives a complete response letter, a clinical hold, or a pivotal trial failure within the next 12 months — events that would likely be signaled by the stock falling more than 35% from today's $61.92 (below roughly $40) over any 252-trading-day window. The call is also strained if the next quarterly filing or management communication indicates cash runway under 12 months without a financing commitment already in place.

Key figures

Market value$8.8B
Revenue, last 12 monthsn/a
Net income, last 12 months−$1.1B
Free cash flow, last 12 months−$974M
Price to earningsn/a
Free cash flow yield−11.1%
Dividend yield0.0%
Operating marginn/a
Return on equity−42.7%
Beta to the S&P 5000.85
Volatility, annualized64.9%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026n/an/a$-1.99−$227M
June 30, 2026n/an/a$-1.97−$237M
March 31, 2026n/an/a$-2.30−$283M
December 31, 2025n/an/a$-1.80−$227M
September 30, 2025n/an/a$-1.56−$147M
June 30, 2025n/an/a$-1.22−$123M
March 31, 2025n/an/a$-1.04−$172M
December 31, 2024n/an/a$-1.02−$115M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

15 ledger entries and 23 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.